- Public Comps
- NetraMark
NetraMark Valuation Multiples
Discover revenue and EBITDA valuation multiples for NetraMark and similar public comparables like Acer Medical, Renalytix, Vanfund Urban Investment, Diagnos and more.
NetraMark Overview
About NetraMark
NetraMark Holdings Inc provides AI-powered insights and software solutions to optimize clinical trial design and outcomes for pharmaceutical sponsors. The company offers AI solutions to trial sponsors, CROs, and biotechnology companies across the globe. It earns revenue from its proprietary NetraAI platform, an advanced machine learning system purpose-built to analyze complex clinical trial data and identify meaningful patient subpopulations.
Founded
2019
HQ

Employees
6
Website
Financials (FY)
EV
$44M
Valuation Multiples
Start free trialNetraMark Financials
NetraMark reported last fiscal year revenue of $313K and negative EBITDA of ($4M).
In the same fiscal year, NetraMark generated ($4M) in EBITDA losses and had net loss of ($4M).
NetraMark P&L
In the most recent fiscal year, NetraMark reported revenue of $313K and EBITDA of ($4M).
NetraMark is unprofitable as of last fiscal year, with EBITDA margin of (1207%) and net margin of (1207%).
Financial data powered by Morningstar, Inc.
NetraMark Stock Performance
NetraMark has current market cap of $47M, and enterprise value of $44M.
Market Cap Evolution
NetraMark's stock price is $0.49.
NetraMark share price increased by 6.6% in the last 30 days, and decreased by 48.4% in the last year.
NetraMark has an EPS (earnings per share) of $-0.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $44M | $47M | -0.0% | 6.6% | 11.0% | -48.4% | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNetraMark Valuation Multiples
NetraMark trades at 141.4x EV/Revenue multiple, and (11.7x) EV/EBITDA.
NetraMark Financial Valuation Multiples
As of September 15, 2026, NetraMark has market cap of $47M and EV of $44M.
NetraMark has a P/E ratio of (12.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified NetraMark Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


NetraMark Margins & Growth Rates
In the most recent fiscal year, NetraMark reported EBITDA margin of (1207%) and net margin of (1207%).
NetraMark Margins
NetraMark Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
NetraMark Operational KPIs
NetraMark's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.7M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
NetraMark Competitors
NetraMark competitors include Acer Medical, Renalytix, Vanfund Urban Investment, Diagnos, Data Horizon, Deepnoid, Senzime, Pathkey.AI, Oncocross and Carelabs.
Most NetraMark public comparables operate across Health Data & Analytics, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 21.0x | - | (40.6x) | - | |||
| 17.0x | 17.0x | (2.4x) | - | |||
| - | - | - | - | |||
| 823.8x | - | (13.2x) | - | |||
| 2.1x | - | 15.1x | - | |||
| 5.6x | 3.0x | (4.3x) | 39.5x | |||
| 5.0x | 4.2x | (4.6x) | (7.9x) | |||
| 1434.0x | - | (29.1x) | - | |||
This data is available for Pro users. Sign up to see all NetraMark competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout NetraMark
| When was NetraMark founded? | NetraMark was founded in 2019. |
| Where is NetraMark headquartered? | NetraMark is headquartered in Canada. |
| How many employees does NetraMark have? | As of today, NetraMark has over 6 employees. |
| Who is the CEO of NetraMark? | NetraMark's CEO is George Achilleos. |
| Is NetraMark publicly listed? | Yes, NetraMark is a public company listed on Toronto Stock Exchange. |
| What is the stock symbol of NetraMark? | NetraMark trades under AIAI ticker. |
| When did NetraMark go public? | NetraMark went public in 2021. |
| Who are competitors of NetraMark? | NetraMark main competitors include Acer Medical, Renalytix, Vanfund Urban Investment, Diagnos, Data Horizon, Deepnoid, Senzime, Pathkey.AI, Oncocross, Carelabs. |
| What is the current market cap of NetraMark? | NetraMark's current market cap is $47M. |
| What is the current revenue of NetraMark? | NetraMark's last fiscal year revenue is $313K. |
| What is the current EV/Revenue multiple of NetraMark? | Current revenue multiple of NetraMark is 141.4x. |
| Is NetraMark profitable? | No, NetraMark is not profitable. |
| How many companies NetraMark has acquired to date? | NetraMark hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies NetraMark has invested to date? | NetraMark hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to NetraMark
Lists including NetraMark
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




